Enliven Therapeutics ELVN EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's EBITDA?
- Enliven Therapeutics (ELVN) reported EBITDA of -$27.81M in Q1 2026.
- How has Enliven Therapeutics's EBITDA changed year-over-year?
- Enliven Therapeutics's EBITDA increased by 12.0% year-over-year, from -$31.62M to -$27.81M.
- What is the long-term trend for Enliven Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Enliven Therapeutics's EBITDA has grown at a 23.5% compound annual growth rate (CAGR), from -$51.34M to -$119.4M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.